drugset
drugset / Trial / NCT05335720

Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)

NCT05335720 ↗

Completed 10 enrolled PT. Daewoong Infion Equilab International · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective study, randomized, using control, open-label, single-center to evaluate the efficacy and safety of EASYEF® in acute wound (split-thickness skin graft donor site). A total of 10 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test cohorts in a ratio of 1:1:1.

Timeline

Start
2019-07-19
Primary completion
2020-03-01
Completion
2020-04-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator NEPIDERMIN Protein / enzyme biologic 50 ug Topical

Indications

No indication recorded.